Abstract
γ-Secretase is responsible for the final cut of the amyloid β-peptide (Aβ) precursor (APP) to produce the Aβ peptide implicated the pathogenesis of Alzheimers disease (AD). Thus, this protease is a top target for the development of AD therapeutics. γ-Secretase is a complex of four different integral membrane proteins, with the multi-pass presenilin being the catalytic component of a novel intramembrane-cleaving aspartyl protease. γ-Secretase cleaves other substrates besides APP, the most notorious being the Notch receptor that is required for many cell differentiation events. Because proteolysis of Notch by γ-secretase is essential for Notch signaling, interference with this process by γ-secretase inhibitors can cause severe toxicities. Thus, the potential of as therapeutic target likely depends on the ability to selectively inhibit Aβ production without hindering Notch proteolysis. The discovery of compounds capable of such allosteric modulation of the protease activity has revived γ-secretase as an attractive target. Structural modification of these secretase modulators through medicinal chemistry should lead to in vivo active agents suitable for clinical trials.
Keywords: Alzheimers disease, Presenilins, Janus kinase 3, COX inhibitors, Amyloid beta
Current Alzheimer Research
Title: γ-Secretase Modulators
Volume: 4 Issue: 5
Author(s): Michael S. Wolfe
Affiliation:
Keywords: Alzheimers disease, Presenilins, Janus kinase 3, COX inhibitors, Amyloid beta
Abstract: γ-Secretase is responsible for the final cut of the amyloid β-peptide (Aβ) precursor (APP) to produce the Aβ peptide implicated the pathogenesis of Alzheimers disease (AD). Thus, this protease is a top target for the development of AD therapeutics. γ-Secretase is a complex of four different integral membrane proteins, with the multi-pass presenilin being the catalytic component of a novel intramembrane-cleaving aspartyl protease. γ-Secretase cleaves other substrates besides APP, the most notorious being the Notch receptor that is required for many cell differentiation events. Because proteolysis of Notch by γ-secretase is essential for Notch signaling, interference with this process by γ-secretase inhibitors can cause severe toxicities. Thus, the potential of as therapeutic target likely depends on the ability to selectively inhibit Aβ production without hindering Notch proteolysis. The discovery of compounds capable of such allosteric modulation of the protease activity has revived γ-secretase as an attractive target. Structural modification of these secretase modulators through medicinal chemistry should lead to in vivo active agents suitable for clinical trials.
Export Options
About this article
Cite this article as:
Wolfe S. Michael, γ-Secretase Modulators, Current Alzheimer Research 2007; 4 (5) . https://dx.doi.org/10.2174/156720507783018299
DOI https://dx.doi.org/10.2174/156720507783018299 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pathophysiology of Transmissible Spongiform Encephalopathies
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Neurobehavioral Consequences Associated with Long Term Tramadol Utilization and Pathological Mechanisms
CNS & Neurological Disorders - Drug Targets Schizophrenia and Bipolar Affective Disorder: Perspectives for the Development of Therapeutics
Current Molecular Medicine “Liking” and “Wanting” Linked to Reward Deficiency Syndrome (RDS): Hypothesizing Differential Responsivity in Brain Reward Circuitry
Current Pharmaceutical Design The Mitochondriotropic Effects of L-carnitine and its Esters in the Central Nervous System
Current Medicinal Chemistry - Central Nervous System Agents PET Radiopharmaceuticals for Personalized Medicine
Current Drug Targets Green Tea, A Medicinal Food with Promising Neurological Benefits
Current Neuropharmacology The Role of Regulatory T Cells in Contact Hypersensitivity
Recent Patents on Inflammation & Allergy Drug Discovery Interleukin-4-Induced Oxidative Stress Via Microglial NADPH Oxidase Contributes to the Death of Hippocampal Neurons In Vivo
Current Aging Science Evidence for Mitochondrial UPR Gene Activation in Familial and Sporadic Alzheimer’s Disease
Current Alzheimer Research The Use of Psychoactive Substances and Illegal Drugs in the Albanian Society
Current Drug Research Reviews Signal Transduction Pathways of Inflammatory Gene Expressions and Therapeutic Implications
Current Pharmaceutical Design Nanostructured Modulators of Neuroglia
Current Pharmaceutical Design The Risk That DSM-5 Will Give Personality Dimensions A Bad Name
Current Psychiatry Reviews Development of Poly(lactide-co-glicolide) Nanoparticles Incorporating Morphine Hydrochloride to Prolong its Circulation in Blood
Current Pharmaceutical Design Commentary [Targeting Opioid Receptors: A New Treatment for Brain Disorders]
CNS & Neurological Disorders - Drug Targets Securinine Derivatives as Potential Anti-amyloid Therapeutic Approach
CNS & Neurological Disorders - Drug Targets Interaction of Prolyl Oligopeptidase with α-Synuclein
CNS & Neurological Disorders - Drug Targets Curcumin Loaded and Co-loaded Nanosystems: A Review from a Biological Activity Enhancement Perspective
Pharmaceutical Nanotechnology Selective Antagonism at Dopamine D3 Receptors as a Target for Drug Addiction Pharmacotherapy: A Review of Preclinical Evidence
CNS & Neurological Disorders - Drug Targets